Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

Histologically confirmed solid tumor with radiographic evidence of metastatic disease

No standard therapy exists (phase I)
Unresectable or metastatic renal cell carcinoma (phase Ib)

PATIENT CHARACTERISTICS:

Karnofsky performance status 70-100%
Absolute neutrophil count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Hemoglobin ≥ 9 g/dL
AST or ALT ≤ 2.5 times upper limit of normal (ULN)
Total cholesterol < 300 mg/dL
Triglycerides < 350 mg/dL
Bilirubin ≤ 1.5 times ULN
Creatinine ≤ 1.5 times ULN OR creatinine clearance > 40 mL/min
Negative proteinuria by dip stick OR total urinary protein ≤ 500 mg
No uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with antihypertensive regimen
No unstable angina pectoris
No symptomatic congestive heart failure (New York Heart Association class III or IV heart disease)
No uncontrolled serious cardiac arrhythmia (symptomatic supraventricular tachycardia or any ventricular tachycardia/fibrillation)
No myocardial infarction in the past 6 months
No uncontrolled diabetes
No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
No active or uncontrolled infection
No uncontrolled hyperlipidemia
No chronic renal disease
No acute or chronic liver disease (e.g., hepatitis or cirrhosis)

No impaired gastrointestinal (GI) function OR GI disease that may significantly alter the absorption of vatalanib or everolimus, including any of the following:

Ulcerative disease
Uncontrolled nausea and vomiting with solid food
Watery diarrhea > 5 times daily
Malabsorption syndrome
Bowel obstruction
Inability to swallow the tablets
No confirmed HIV infection
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception
No other concurrent severe and/or uncontrolled medical condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Recovered from prior therapy
No prior antivascular endothelial growth factor therapy
More than 4 weeks since prior major surgery* (laparotomy)
More than 2 weeks since prior minor surgery*
More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)
More than 6 weeks since prior antibody therapy
More than 2 weeks since prior biologic/immunotherapy
More than 2 weeks since prior limited-field radiotherapy
More than 4 weeks since prior full-field radiotherapy
More than 4 weeks since prior investigational agents
Prior transfusions allowed provided blood counts are stable for > 2 weeks
Concurrent epoetin alfa allowed

No concurrent warfarin or similar oral anticoagulants that are metabolized by the cytochrome P450 system

Heparin and low molecular weight heparin allowed NOTE: *Insertion of a vascular access device is not considered major or minor surgery